Monoclonal antibodies against the active site of factor XI and uses thereof
The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of th...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English |
Published |
13.07.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies. |
---|---|
Bibliography: | Application Number: US201716087686 |